Harno-Tasihin J, Siregar L, Paajanen M, Arkkila P, et al. Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses. Scand J Gastroenterol 2023 Nov 25:1-8. doi: 10.1080/00365521.2023.2285229.
PMID: 38006219